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Abstract
Background: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel drug delivery system able to
induce regression of peritoneal metastasis (PM) in the salvage situation. The aim of this study was to determine the
clinical characteristics, tumor histology, and extent of disease of the patients having undergone cytoreductive
surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) after “neoadjuvant” PIPAC.
Methods: This study was performed at a single institution, tertiary center. In a prospective registry, retrospective
analysis was done. PIPAC indication was restricted to patients in the salvage situation who were not eligible for
cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Results: Nine-hundred sixty-one PIPAC sessions were successfully performed in 406 patients: 21 patients (5.2 %)
were scheduled for CRS and HIPEC. Twelve of these patients had a low PCI (mean 5.8 ± 5.6). The remaining nine
patients showed an advanced peritoneal disease (mean PCI 14.3 ± 5.3) at initial laparoscopy. After repeated PIPAC
(mean number of cycles 3.5 ± 0.9), radiological tumor regression was observed in 7/9 patients and major
histological regression was observed in 8/9 patients, so that secondary CRS and HIPEC became possible.
Conclusions: PIPAC might be used as a neoadjuvant therapy before CRS and HIPEC in order to improve the outcome
of CRS and HIPEC, to select patients with chemosensitive, biologically favorable tumors, to extent the indications of
CRS and HIPEC in the presence of diffuse small bowel involvement, and to reduce the extent of cytoreductive surgery.
Keywords: Peritoneal metastasis, Intraperitoneal chemotherapy, Cytoreductive surgery, Hyperthermic intraperitoneal
chemotherapy (HIPEC), Pressurized intraperitoneal aerosol chemotherapy (PIPAC), Cisplatin, Doxorubicin
Background
Peritoneal metastasis is a common and dismal evolution
of several gastrointestinal and gynecological tumors, in-
cluding gastric, ovarian, colorectal, hepatobiliary, pancre-
atic, uterine, urological, and other cancers [1]. The therapy
of peritoneal metastasis is largely palliative; with the aim of
prolonging life and preserving its quality. Most patients re-
ceive platin-based, combination systemic chemotherapy
[2]. In spite of this guideline-recommended therapy,
they die within months after diagnosis of peritoneal dis-
semination [3].
Almost 70 years ago, intraperitoneal chemotherapy
has been discovered as an alternative therapeutic option
in peritoneal metastasis [4]. In the meantime, a significant
pharmacological advantage of intraperitoneal chemother-
apy was documented in the preclinical model, and numer-
ous clinical studies have delivered promising clinical
results (reviewed in [5]). In the last 30 years, cytoreductive
surgery (CRS) combined with hyperthermic intraperito-
neal chemotherapy (HIPEC) has been increasingly used.
On the basis of long-term survivors, some authors see a
curative role for this combined therapy [6]. However, the
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level of evidence of CRS and HIPEC is still relatively low,
and the complication rate remains significant so that this
therapy is not accepted by all oncologists [7].
In spite of the above controversies, there is a broad
agreement that CRS and HIPEC should only be offered
to highly selected patients, taking into consideration the
tumor type, the extent of disease, and the general condi-
tion of the patient [8]. In particular, diffuse invasion of
the small bowel represent a contraindication for CRS and
HIPEC because of the dilemma between complete cytore-
duction and extensive resection of the small bowel—
which is not compatible with life [9]. Thus, there is an ur-
gent need for novel therapies for the majority of peritoneal
metastasis patients not eligible for CRS and HIPEC.
Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
is an innovative approach delivering chemotherapy into
the peritoneal cavity as a pressurized normothermic
aerosol [10]. Early studies in patients with peritoneal
metastases secondary to ovarian [11] or other abdom-
inal cancers [12, 13] have shown some efficacy and good
tolerability, in particular PIPAC does not induce signifi-
cant neither liver or renal toxicity [14] nor gastrointestinal
symptoms [15]. In summer 2015, an independent technol-
ogy assessment concluded that “As an experimental tech-
nique, PIPAC has been used in patients who are quite ill
and have already failed multiple treatment regimes, but it
may not be limited to that group of patients in the future.
PIPAC may have significant advantages over existing
chemotherapy techniques, which are painful and disabling,
and associated with long length of stay and a high risk of
adverse events” [16]. Several clinical trials on PIPAC in
various indications are ongoing [17–22]. However, it is dif-
ficult to assess the safety and effectiveness of PIPAC since
no comparative studies have been published so far.
Our institution is pioneering the potential fields of the
application of PIPAC, including defining indications and
contraindications, chances and risks, as well as success
and failures of this therapy. We have observed repeatedly
that some patients who were primarily not eligible for
CRS and HIPEC, most often because of small bowel in-
volvement, could be treated after repeated PIPAC applica-
tion with CRS and HIPEC.
The general aim of this study was to determine the clin-
ical characteristics, tumor histology, and extent of disease
of the patients having undergone CRS and HIPEC after
“neoadjuvant” PIPAC. We also determined the survival of
these patients having received this sequential therapy, in
association or not with systemic palliative chemotherapy.
Methods
Study design
Retrospective analysis of data obtained within the frame-
work of a prospective registry (observational study). No
blinding was applied.
Setting
This study was performed at a university hospital, tertiary
care center, certified interdisciplinary center for therapy of
peritoneal disease.
Patient selection
Before therapy, each patient was presented in the inter-
disciplinary tumor board and the indication for therapy
was decided on a case-by-case, individual basis. Eligible
patients were treated with cytoreductive surgery (CRS)
and hyperthermic intraperitoneal chemotherapy (HIPEC).
No inclusion and exclusion criteria were pre-defined. All
consecutive patients admitted for PIPAC and/or HIPEC in
our institution between February 3, 2010, and March 16,
2016, were included.
Technique of PIPAC
The technique of PIPAC has been described elsewhere
[23]. Shortly, after insufflation of a 12 mmHg CO2
pneumoperitoneum with open access or with Veres
needle, two balloon safety trocars (5 and 12 mm, Applied
Medical, Düsseldorf, Germany) were inserted into the
abdominal wall. The extent of peritoneal carcinomatosis
(PCI score) was determined based on lesion size and dis-
tribution [24]. Peritoneal biopsies were taken in all four
quadrants for histological examination, and a local par-
tial peritonectomy of several square centimeters was
performed routinely to improve accuracy of anatomo-
pathology. A 9-mm aerosolizer (Capnopen®, Capnomed,
Villingendorf, Germany) was connected to an intravenous
high-pressure injector (Arterion Mark 7®, Medrad, Bayer,
Germany) and inserted into the abdomen through an ac-
cess port. Following safety measures were taken to exclude
any exposure of the operating team [25]. First, tightness of
the abdomen was documented via a zero flow of CO2.
Second, the procedure was performed in an operating
room equipped with laminar air flow. Third, chemother-
apy injection was remote-controlled and nobody remained
in the operating room during the application. For pa-
tients with ovarian [11], gastric [12], and hepatobiliary-
pancreatic [26] cancers, a pressurized aerosol contain-
ing doxorubicin at a dose of 1.5 mg/m2 body surface in
a 50 ml NaCl 0.9 % solution followed by cisplatin at a
dose of 7.5 mg/m2 body surface in a 150 ml NaCl 0.9 %
solution was applied via aerosolizer and injector. For
colorectal and appendiceal cancer patients, oxaliplatin
at a dose of 92 mg/m2 was applied instead of cisplatin
and doxorubicin, as described elsewhere [13]. Flow rate was
30 ml/min and maximal upstream pressure was 200 psi
(13.8 bar). The therapeutic capnoperitoneum was then
maintained for 30 min at 37 °C. Then, the chemotherapy
aerosol was exsufflated via a closed line over two sequential
microparticle filters into the airwaste system of the hospital.
Finally, trocars were retracted and laparoscopy was ended.
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No drainage of the abdomen was applied. If possible, the
PIPAC procedure was repeated after 6 weeks.
Technique of CRS
Cytoreductive surgery was performed as described else-
where [27], with the aim of complete cytoreduction
(CC-0). When necessary, radical cytoreduction was asso-
ciated with multivisceral resection, including resection
of the diseased peritoneum in all the four abdominal
quadrants, in the pelvis and a total omentectomy. Normal
appearing peritoneum was not removed. Visceral resec-
tions included right colectomy, sigmoid colon resection,
splenectomy, distal pancreatectomy, atypical liver resec-
tion, partial gastrectomy, and partial diaphragmatic resec-
tions. However, the aim was to preserve as many organs
as possible. In particular, tumor nodules located on the
peritoneal surface of the small and large bowel were re-
moved without organ resection when no infiltration was
present.
Technique of HIPEC
Following CRS, HIPEC was performed using the closed
technique for 60 min at a temperature of 41–43 °C using
extracorporal circulation of liquid solutions. HIPEC was
initiated after bowel reconstruction and abdominal clos-
ure. The drugs applied were oxaliplatin 360 mg/m2 body
surface for appendiceal and colorectal cancer cases or a
combination of cisplatin 75 mg/m2 body surface and
doxorubicin 15 mg/m2 body surface in the other cancer
types. In colorectal cases, 5-fluorouracil was infused im-
mediately after the procedure to enhance the effects of
hyperthermic intraperitoneal oxaliplatin, as described
elsewhere [28].
Completeness of cytoreduction
Completeness of cytoreduction score (CC score) was
determined according to Sugarbaker [29]: CC-0: no re-
sidual disease; CC-1: residual disease <2.5 mm; CC-2:
residual disease >2.5 mm.
Karnofsky index (KI)
The Karnofsky index [30] was determined at the time
point of hospital admission in all patients and was used
for estimating prognosis and defining therapeutic goals.
The index scale ranges from 0 (death) to 100 % (no
restriction).
Follow-up
Patients were followed up until March 21st, 2016, or
until death. This short follow-up is explained by the pro-
spective nature of the prospective PIPAC registry, which
is updated daily.
Radiological criteria of tumor regression
Repeated CT scans were performed at 3 to 6 months
interval, and radiological response was assessed accord-
ing to RECIST 1.1 criteria [31].
Histological criteria of tumor regression
Macroscopically, it was possible to determine a general
pattern of tumor regression (glassy tumor nodes with
hard consistence, progressive scarring, disparition of tumor
neovessels, and vanishing of ascites). However, it is not
possible to distinguish as a surgeon between scar tissue
and residual tumor node. For such purpose, histological
analysis is mandatory. The histopathological response
(regression grading) was assessed by an independent
pathologist as follows: tumor regression grading (TRG)
0 indicated a tumor without regression; TRG1 indicated
a dominant tumor mass with obvious fibrosis and/or
vasculopathy; TRG2 indicated dominantly fibrotic changes
with few tumor cells or groups that were easy to identify;
TRG3 described only very few tumor cells that were diffi-
cult to locate in the fibrotic tissue with/without mucous
substance; and TRG4 indicated that only a fibrotic mass
without tumor cells was present, i.e., total regression or
response [32]. The pathologist was blinded to the macro-
scopic and clinical outcomes but was able to compare the
biopsies to the previous PIPACs. At the time patients were
operated on, the Peritoneal Regression Grading Score
(PRGS) had not yet been proposed [33].
Statistical analysis
This is a retrospective case series. No size sample was
defined a priori, since this is an exploratory study aimed at
generating pilot data. Statistics were performed using the
SPSS version 22.0 software. Descriptive statistics included
mean and standard deviation, median, percentiles, and
confidence interval. Survival statistics were computed and
plotted according to Kaplan-Meyer. For survival statistics,
a log-rank test (with or without linear trend depending
on the question) was calculated. P < 0.05 was considered
significant.
Results
During the period of investigation, 961 PIPAC sessions
were successfully performed in 406 patients, in the mean
of 2.3 PIPAC cycles per patient. Out of these 406 pa-
tients treated with PIPAC, 21 (5.2 %) were scheduled for
CRS and HIPEC during the later course of therapy. Dur-
ing the same period of time in our institution, 36 other
CRS and HIPEC were performed in 32 patients, inde-
pendently from any PIPAC indication or therapy. CRS
and HIPEC were repeated in four patients. The charac-
teristics of all 53 patients treated with CRS and HIPEC
are summarized in Table 1. A flow diagram is presented
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in Fig. 1, which précises the organ of origin of peritoneal
metastasis
Therapy and results
When examining in detail the clinical files of all 53 pa-
tients treated with CRS and HIPEC, we found that 21
patients were treated after neoadjuvant PIPAC in this
palliative situation. Out of these 21 patients, 12 patients
were scheduled for CRS and HIPEC after the first PIPAC
because the intraoperative finding showed a low PCI
(mean 5.8 ± 5.6). Clearly, these cases had not been evalu-
ated previously for possible therapy with CRS and HIPEC.
In these 12 patients, CRS and HIPEC were indeed possible
independently of previous PIPAC, even though a single
PIPAC cycle was performed in these patients.
PIPAC as a neoadjuvant therapy
The remaining nine patients showed at initial laparos-
copy such an extent of peritoneal disease that they were
no candidates for primary CRS and HIPEC. At first
PIPAC, PCI was relatively high (mean 14.3 ± 5.3) and
complete cytoreduction (CC-0) did not appear feasible,
in particular because of diffuse small bowel involvement.
Six of these nine patients had colorectal or appendiceal
Table 1 Clinical characteristics of 53 consecutive patients treated with CRS and HIPEC between February 2010 and March 2016 at
our institution
Patients All Primary CRS and HIPEC Secondary CRS and HIPEC (after PIPAC)
Number of patients 53 32 21
Age (years) 55.8 ± 9.5 55.3 ± 9.6 56.3 ± 9.5
Sex (M:F) 20:33 8:24 12:9
Karnofsky index (%) 86.0 ± 10.1 85.9 ± 11.0 92.1 ± 5.6
Organ
-Ovarian 15 (28 %) 11 (35 %) 4 (19 %)
-Colorectal/appendix 19 (36 %) 8 (25 %) 11 (52 %)
-PMP 9 (17 %) 7 (22 %) 2 (10 %)
-Gastric 6 (11 %) 3 (9 %) 3 (14 %)
-Mesothelioma 4 (8 %) 3 (9 %) 1 (5 %)
Peritoneal Carcinomatosis index (initial PCI) 12 ± 8 13.3 ± 9.0 11.5 ± 6.4
Ascites (ml) 147 ± 466 0 ± 0 198 ± 536
Fig. 1 Indications for PIPAC (a1), for CRS and HIPEC (b) for CRS and HIPEC after “neoadjuvant” PIPAC (a2). In our institution, primary indications
for PIPAC and HIPEC are relatively similar with a majority of ovarian cancers. However, indication for PIPAC was 12× more frequent than indication for
CRS and HIPEC. Secondary CRS and HIPEC were performed in 5.1 % of PIPAC patients with a majority of colorectal cancer patients. PIPAC might allow
secondary CRS and HIPEC in selected patients with colorectal cancer who were not eligible primarily for such procedure
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cancer, one ovarian cancer, one malignant peritoneal
mesothelioma, and one advanced pseudomyxoma perito-
nei. In these nine patients, an objective tumor regression
was observed after repeated PIPAC (mean number of cy-
cles 3.5 ± 0.9), so that secondary CRS and HIPEC were
possible. The procedures are summarized in Table 2.
Objective radiological tumor regression according to
RECIST 1.1 criteria was observed in seven out of nine
patients. An example of such regression is shown in Fig. 2.
Objective major histological regression was observed in
eight out of nine patients, minor regression in the last
patient.
Survival
Figure 3 shows the overall probability of survival of 53
patients treated with CRS and HIPEC, grouped accord-
ing to the organ of origin. Best survival was observed in
pseudomyxoma peritonei patients (n = 9), followed by
ovarian (n = 15), and colorectal (n = 19) cancer patients.
In this retrospective cohort, selected patients with gastric
cancer (n = 6) and malignant mesothelioma (n = 4) had
the worst prognosis. One patient died in the hospital on
postoperative day 33.
We also examined the survival probability in the patients
with peritoneal metastasis of colorectal origin (n = 19) de-
pending on a neoadjuvant therapy with PIPAC before CRS
and HIPEC. The survival curve shows that the patients
with extensive disease, pre-treated with PIPAC, had a
worse prognosis than those treated primarily with CRS and
HIPEC in the presence of limited disease (Fig. 4). It has to
be noted that these patients are not directly comparable
since the patients treated with neoadjuvant PIPAC were
primarily no candidates for CRS and HIPEC because of the
extension of peritoneal disease. Interestingly, this differ-
ence in survival probability does not reach statistical
significance, but this should be interpreted with caution
because of the small number of patients and of the
retrospective nature of this analysis.
We performed an exploratory multivariate analysis in
order to identify potential prognostic factors for survival
in this cohort of 53 patients. Three variables were identi-
fied that approached statistical significance: therapy with
neoadjuvant PIPAC (p = 0.08), PCI score (p = 0.19), and
organ of origin (p = 0.27).
Discussion
This exploratory analysis is the first evaluating a poten-
tial role of PIPAC as a neoadjuvant therapy in peritoneal
metastasis patients not eligible for cytoreductive surgery
and hyperthermic intraperitoneal chemotherapy (HIPEC).
Although these pilot data should be considered prelimin-
ary and interpreted with caution, a few interesting obser-
vations can be done.
First, in our institution, PIPAC was performed much
more frequently than CRS and HIPEC. In fact, there
were 12 times more PIPAC than HIPEC procedures.
This suggests that the indications for PIPAC might be
more common than those for CRS and HIPEC. It has to
be noted that, as a priority, we performed CRS and
HIPEC in all eligible patients, rather than PIPAC. Thus,
it appears that PIPAC can be proposed to many patients
who are not eligible for CRS and HIPEC.
Second, we know from previous studies that about
three quarters of patients with peritoneal metastasis in
the salvage situation develop major or complete intra-
peritoneal tumor regression after repeated PIPAC ther-
apy, as assessed by histology [10–13]. In the present
cohort of patients, many patients were not primarily eli-
gible for CRS and HIPEC because of the extent of peri-
toneal disease, in particular because of diffuse small
Table 2 CRS and HIPEC procedures performed in 53 patients with (n = 21) or without (n = 32) “neoajuvant” PIPAC
Patients All
(n = 53)
Primary CRS and HIPEC
(n = 32)
Secondary CRS and HIPEC (after PIPAC)
(n = 21)
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bowel involvement. An important finding of this case
series is that CRS and HIPEC were possible in a sub-
group of patients after repeated PIPAC. Secondary CRS
and HIPEC were indeed only possible in a small number
of patients (5.1 % of all patients treated with PIPAC dur-
ing the period of time under observation). However, this
might be a message of hope for patients and HIPEC sur-
geons, showing that PIPAC might be able to control in
some cases diffuse small bowel involvement, a feature
considered as a critical to allow complete cytoreduction
[27, 34]. Interestingly, the majority of these patients have
peritoneal metastasis of colorectal cancer origin, suggest-
ing a potential role of PIPAC as a neoadjuvant therapy
in this particular indication.
Third, probability of overall survival was lower in the
colorectal cancer patients having received neoadjuvant
therapy with PIPAC before CRS and HIPEC. This obser-
vation is all but a surprise since these patients had a
more extensive disease than patients who were treated
primarily with CRS and HIPEC. In fact, the difference
between both survival curves did not achieve signifi-
cance. Although the number of patients is limited, this
suggests that PIPAC might have a positive impact on
survival in these selected patients. This hypothesis has
now to be confirmed by adequate prospective studies.
Fourth, the mean number of PIPAC cycles needed to
transform diffuse intraperitoneal metastasis into local-
ized diseased approached four, or a time period of
Fig. 2 Contrast-enhanced CT scans of a 57-year-old male patient with peritoneal metastasis of an appendiceal cancer. a Image after 12 cycles of
combination palliative chemotherapy with FOLFOX4 and 6 cycles of FOLFIRI showing active disease with massive ascites (asterisk). b Evolution
after 5 cycles of PIPAC with low-dose cisplatin and doxorubicin showing partial tumor response according to RECIST 1.1 criteria, in particular
ascites control. c Postoperative image after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). d CT scan 6 months after
CRS and HIPEC showing beginning recurrence (minimal ascites and tumor node on the lateral liver surface). The patient survived 46 months after
diagnosis, 25 months after first PIPAC, and 18 months after CRS and HIPEC
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approximately 4.5 to 6 months. Clearly, peritoneal me-
tastasis needs a relatively long time to go into regres-
sion under PIPAC therapy.
Finally, it has to be mentioned that three patients with
signet-ring cell cancer (two with gastric cancer, one with
appendiceal cancer) developed early and explosive tumor
recurrence after secondary CRS and HIPEC, suggesting
that this aggressive surgical procedure might not have
been helpful in these patients. Although objective tumor
control had been achieved by repeated PIPAC application,
biology of signet-ring cell remains aggressive [35]. Cre-
ation of peritoneal wounds, stimulation of tumor growth,
angiogenesis, and postoperative impairment of immune
defenses might explain this observation. Clearly, further
experimental and clinical work is needed on this question.
Taken together, these preliminary results suggest that
PIPAC might be used as a neoadjuvant therapy before
CRS and HIPEC in the future. Of course, the role of
PIPAC and systemic neoadjuvant chemotherapy in peri-
toneal metastasis has to be evaluated in adequate, spe-
cific clinical trials. The aim of such neoadjuvant therapy
would be to improve outcome of CRS and HIPEC, to se-
lect patients with chemosensitive, biologically favorable
tumors, to extent the indications of CRS and HIPEC to
some patients with diffuse small bowel involvement, and
finally, to reduce the extent of surgery.
Against this framework, it has to be emphasized that
the technical feasibility and the efficacy of PIPAC are
largely depending on the degree of enteroenteral and
enteroparietal adhesions. In 12 % of our patients, abdom-
inal access was not possible due to adhesions. Moreover,
only exposed peritoneal surfaces that can be reached by
the aerosol can be treated with PIPAC. Although we are
not able at this point of time to stratify response after
PIPAC depending on the degree of adhesions, it might
make sense to apply PIPAC as early as possible in the
therapeutic chain. In our experience, it is possible to per-
form PIPAC before CRS and HIPEC in the vast majority
of patients. The opposite is not true since massive adhe-
sions develop usually after extensive peritonectomy. This
is unfortunate for patients developing intraabdominal re-
currence after incomplete cytoreduction during CRS and
HIPEC.
Finally, it appears that PIPAC is able to stabilize quality
of life of a significant number of patients with peritoneal
metastasis [15]. This appears to be an important feature in
the palliative setting. Against this framework, it has to be
noted that a recent phase-2 trial [36] with PIPAC with
low-dose cisplatin and doxorubicin combined with sys-
temic palliative chemotherapy (XELOX) has shown a
median overall survival (13 months) superior to the fig-
ures reported after CRS and HIPEC (7.9 months) [37],
and this in unselected patients with a poorer risk pro-
file. Thus, it is reasonable to formulate the hypothesis
Fig. 3 Overall survival of 53 patients treated with CRS and HIPEC,
grouped according to the organ of origin. Best survival is observed
in pseudomyxoma peritonei patients (n = 9), followed by ovarian
(n = 15) and colorectal (n = 19) cancer patients. In this retrospective
cohort, selected patients with gastric cancer (n = 6) and malignant
mesothelioma (n = 4) have the worst prognosis
Fig. 4 Overall survival of 19 patients with peritoneal metastasis
treated with CRS and HIPEC, with (green curve) or without (blue curve)
“neoadjuvant” PIPAC. As expected, patients primarily not eligible for
CRS and HIPEC and treated with neoadjuvant PIPAC seem to have a
worse prognosis than the other patients. However, this difference does
not reach statistical significance in this small cohort of patients
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that some patients could have achieved the same survival
with a better quality of life, if they were kept on PIPAC
treatment instead of CRS and HIPEC.
Conclusions
In conclusion, we propose that neoadjuvant PIPAC, com-
bined or not with systemic chemotherapy, might be a
promising approach for patients with peritoneal metasta-
sis, and might allow to reduce diffuse peritoneal spreading
to a more localized tumor involvement, so that secondary
CRS and HIPEC might become possible. PIPAC is a sim-
ple, safe procedure and the tolerance of the procedure is
usually excellent. Since PIPAC is repeated at 6-week inter-
val, it creates proper methodological preconditions for
assessing tumor response to locoregional and/or systemic
chemotherapy. We will now design a clinical trial evaluat-
ing a potential place of PIPAC as a neoadjuvant therapy in
gastric cancer with synchronous peritoneal metastasis.
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